Recently, the news that the domestic team discovered the new crown treatment drug “Ceptophyllin” has become popular on the Internet. Patent information shows that 10uM (micromol/L) of phlebophyllin inhibits the replication of coronavirus by a factor of 15,393 times. Professor Tong Yigang, the discoverer, said in an interview: “In layman’s terms, this number can be understood as if there were 15,393 viruses without the fenugreek drug, when the 10 micromol/liter fenugreek drug was used, the number of viruses would be only 1. That is to say, a very small amount of fenugreek can prevent the amplification and spread of the new coronavirus.” Some reports also mentioned that from the current research data, the drug’s ability to inhibit the new coronavirus is found in all human beings. It ranks high among the new coronavirus inhibitors. Once the news was announced, “Qianjin Tensu” appeared on the hot search several times, and many stocks such as North China Pharmaceutical, Fangsheng Pharmaceutical, Buchang Pharmaceutical, and Qianjin Pharmaceutical once hit their daily limit. However, there are also many questions, such as when will new drugs be clinical and marketed? How many theoretical values can be achieved in human trials and so on. According to reports, Fan Huahao, the second inventor of the patent, had previously posted on social media .
[related_posts_by_tax taxonomies=”post_tag”]
The post Is “Qianjintiansu” a new crown medicine or a blank check?Professionals: still far from clinical appeared first on Gamingsym.